X4 Posts Corporate Presentation With Detailed Phase 2 Data Supporting 4WARD Pivotal Trial
XFOR sits 29% above its 52-week low of $2.8 on elevated volume (3.1× avg).
Summary
X4 Pharmaceuticals filed a corporate presentation detailing Phase 2 data showing mavorixafor normalized neutrophil counts and enabled G-CSF dose reductions in chronic neutropenia patients, supporting the streamlined 126-patient 4WARD Phase 3 trial.
Key Events · Product Development and Regulatory · XFOR
-
Phase 2 Data Detailed
Mavorixafor monotherapy raised mean ANC to normal levels (≥1,500 cells/µL) at months 3 and 6 in the 23-patient Phase 2 study; 75% of eligible patients (9 of 12) reduced G-CSF dosing, with 3 stopping entirely.
-
4WARD Trial Streamlined
The FDA agreed to reduce the pivotal 4WARD Phase 3 trial from 176 to 126 patients while maintaining >96% statistical power on both primary endpoints (ANC response and annualized infection rate).
-
Market Opportunity Quantified
Presentation identifies ~15,000 U.S. patients with moderate-to-severe chronic neutropenia as the target market for mavorixafor, with oral treatment ranked as the top unmet need by 95 surveyed hematologists.
-
Financial Position Confirmed
Cash of $208M as of June 30, 2026, with fully diluted common stock outstanding of 145.6M shares; runway expected into 2029.
Analysis · XFOR · Life Sciences
The corporate presentation filed as Exhibit 99.1 provides the most detailed look yet at mavorixafor's Phase 2 proof-of-concept data in chronic neutropenia. Monotherapy raised mean ANC to normal levels (≥1,500 cells/µL) at months 3 and 6, and 75% of eligible patients reduced G-CSF dosing — with three stopping entirely — while maintaining normal ANC. These data underpin the FDA's recent agreement to shrink the 4WARD Phase 3 trial from 176 to 126 patients, a change that accelerates the path to a potential approval in late 2028/early 2029. The presentation also quantifies the U.S. target market at ~15,000 patients and confirms a $208M cash position with runway into 2029, removing near-term financing risk.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1944 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XFOR was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.5M. The 52-week trading range was $2.80 to $4.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.